Breast Cancer Clinical Trials
If you are a patient at Mount Auburn Hospital and have been diagnosed with breast cancer you may be eligible to participate in a clinical trial.
Information about clinical trials:
What is a clinical trial?
A clinical trial is a plan of care to study of the effects of a test or treatment. These include safety, efficacy, and/or quality of life. Patients are selected to participate based on diagnosis and other criteria.
Who pays for clinical trials?
Funding comes from many sources including the federal government and private industry. Care may be provided free to the patient, and sometimes patients are compensated as well for their participation.
Should I participate in clinical research?
You should know that participation in a clinical trial is strictly voluntary. You must be told about all aspects of the clinical trial so that you can make an informed decision. If you choose to participate, the Institutional Review Board protects your rights and safety. You have a right to leave the study at any time.
For more information
Please call Kirsten Chervinsky, RN, Clinical Research Nurse
617-499-6708 or firstname.lastname@example.org
Currently open clinical trials for the diagnosis of Breast Cancer
M.M.P. Urine Study – Patients with a diagnosis of Metastatic Breast Cancer, who have a new diagnosis or are starting a new medication of any kind. This study involves 6 urine samples to be collected over a year. Understanding the role of Urinary metalloproteinase (MMP) patterns may:
- Identify women with precursor lesions at increased risk for progression to invasive disease
- May identify patients with invasive disease at higher risk for distant metastases who would be candidates for more aggressive therapy
- Could be used to monitor breast cancer patients in remission, especially as targeted therapies, such as anti-angiogenic therapy and MMP inhibitors are added to our treatment armamentarium
- Mammoprint Study -Patients being treated for Breast Cancer and have an OncotypeDX intermediate score. Clarification of an intermediate Onctotype Score can assist with treatment decisions. ClinicalTrials.gov Identifier: NCT01617954
Bariatric Urine Study - female, postmenopausal, with a BMI ≥ 35 and is a candidate for Bariatric surgery or starting bariatric medical treatment/diet. This study involves 4 urine samples to be collected over a year. This study will add to the body of knowledge regarding the role of obesity as a risk for Breast Cancer.
Currently open clinical trials for the treatment of Breast Cancer
Oral Adherence – patients who are starting a new oral medication for the treatment or prevention of Breast Cancer. This study involves three visits, each a month apart for a medication review, pill count, and survey.
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer – this is a research study about Trastuzumab (Herceptin). The main purpose of this study is to learn if adding a targeted therapy, trastuzumab (Herceptin), to standard treatment with chemotherapy for early stage, HER2-low Breast Cancer, will prevent breast cancer from returning. ClinicalTrials.gov Identifier: NCT01275677
AIMSS (A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms) - This research is being done to find out what effects, good and/or bad, that anastrozole has, and whether genes can help explain these effects. Women who are; African American or Asian, prescribed the aromatase inhibitor anastrozole as treatment for Breast Cancer, and are postmenopausal may join. ClinicalTrials.gov Identifier: NCT01824836